Limitations, agreements, and source contact

Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) · Source last updated 2014-01-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

limitations And Caveats

description

Trial closed early after 58 patients were enrolled due to slow accrual and shortage of pegylated liposomal doxorubicin. Only 54 participants had cytogenetics and fluorescence in situ hybridisation (FISH) results available for risk stratification.

point Of Contact

email

melissa.alsina@moffitt.org

organization

H. Lee Moffitt Cancer Center and Research Institute

phone

813-745-6886

title

Melissa Alsina, M.D.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice